Follow-on glatiramer acetate
Open Access
- 23 November 2018
- journal article
- other
- Published by Elsevier in eNeurologicalSci
- Vol. 13, 51-52
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with CopaxoneeNeurologicalSci, 2018
- Switching from branded to generic glatiramer acetate: 15-month GATE trial extension resultsMultiple Sclerosis Journal, 2017
- Equivalence of Generic Glatiramer Acetate in Multiple SclerosisJAMA Neurology, 2015
- GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosisMultiple Sclerosis and Related Disorders, 2015
- Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosisAnnals of Neurology, 2013
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disabilityNeurology, 1998
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995